Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 7/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | USP7 | Q93009 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | F7 | P08709 | 1/20 | 0.36 |
| ▸ | F3 | P13726 | 1/20 | 0.36 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.36 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.36 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22401242 | 0.83 | NNMT (0.42) | NNMTSMN1; SMN2PARP10TSHREPHX2 | |
| SCHEMBL14095724 | 0.80 | KMT2A (0.37) | TSHRL3MBTL1 | |
| SCHEMBL186656 | 0.80 | ALDH1A1 (0.52) | SMN1; SMN2KDM4E | |
| SCHEMBL7092189 | 0.79 | EPHX2 (0.44) | NNMTSMN1; SMN2PARP10EPHX2LMNA | |
| SCHEMBL28869347 | 0.78 | PRSS1 (0.42) | F7F3 | |
| SCHEMBL4132044 | 0.78 | MAPT (0.37) | LMNAL3MBTL1 | |
| SCHEMBL31510758 | 0.77 | NNMT (0.44) | NNMTSMN1; SMN2PARP10TSHRKDM4E | |
| SCHEMBL669121 | 0.77 | NNMT (0.52) | NNMTSMN1; SMN2TSHRLMNAKDM4E | |
| SCHEMBL3407188 | 0.76 | NNMT (0.56) | NNMTSMN1; SMN2TSHRLMNAKDM4E | |
| SCHEMBL2717056 | 0.75 | PARP10 (0.53) | NNMTSMN1; SMN2PARP10TSHREPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114502158-A | IRAK degradation agent and application thereof | 凯麦拉医疗公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3174886-B1 | 2-OXA-5-AZABICYCLO[2.2.1]HEPTAN-3-YL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-02-17 | — | — | EP | disclosed |
| CN-106661043-B | 2-oxa-5-azabicyclo [2.2.1] hept-3-yl derivatives | 豪夫迈·罗氏有限公司 | 2020-01-17 | — | — | CN | disclosed |
| CN-106459073-B | 5- oxa- -2- azabicyclics [2.2.2] octyl- 4- bases and 5- oxa- -2- azabicyclics [2.2.1] hept- 4- radical derivatives as TAAR1 conditioning agents | 豪夫迈·罗氏有限公司 | 2018-11-13 | — | — | CN | disclosed |
| EP-3149002-B1 | 5-OXA-2-AZABICYCLO[2.2.2]OCTAN-4-YL AND 5-OXA-2-AZABICYCLO[2.2.1]HEPTAN-4-YL DERIVATIVES AS TAAR1 MODULATORS | HOFFMANN LA ROCHE (CH) | 2018-04-25 | — | — | EP | disclosed |
| US-9790230-B2 | 2-oxa-5-azabicyclo[2.2.1]heptan-3-yl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-10-17 | — | — | US | disclosed |
| EP-3174886-A1 | 2-OXA-5-AZABICYCLO[2.2.1]HEPTAN-3-YL DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2017-06-07 | — | — | EP | disclosed |
| US-9663530-B2 | 5-oxa-2-azabicyclo[2.2.2]OCTAN-4-yl and 5-oxa-2-azabicyclo[2.2.1]heptan-4-yl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20170137435-A1 | 2-OXA-5-AZABICYCLO[2.2.1]HEPTAN-3-YL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-05-18 | — | — | US | disclosed |
| CN-106661043-A | 2-oxa-5-azabicyclo[2.2.1]heptan-3-yl derivatives | 豪夫迈·罗氏有限公司 | 2017-05-10 | — | — | CN | disclosed |
| EP-3149002-A1 | 5-OXA-2-AZABICYCLO[2.2.2]OCTAN-4-YL AND 5-OXA-2-AZABICYCLO[2.2.1]HEPTAN-4-YL DERIVATIVES AS TAAR1 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-04-05 | — | — | EP | disclosed |
| US-20170066775-A1 | 5-OXA-2-AZABICYCLO[2.2.2]OCTAN-4-YL AND 5-OXA-2-AZABICYCLO[2.2.1]HEPTAN-4-YL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-03-09 | — | — | US | disclosed |
| CN-106459073-A | 5-oxa-2-azabicyclo[2.2.2]octan-4-yl and 5-oxa-2-azabicyclo[2.2.1]heptan-4-yl derivatives as TAAR1 modulators | 豪夫迈·罗氏有限公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-3119757-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC AND RELATED DISORDERS | Pfizer Inc. (US) | 2017-01-25 | — | — | EP | disclosed |
| WO-2016016292-A1 | 2-OXA-5-AZABICYCLO[2.2.1]HEPTAN-3-YL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-02-04 | — | — | WO | disclosed |
| WO-2016015333-A1 | 2-OXA-5-AZABICYCLO [2.2.1] HEPTAN-3-YL DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2016-02-04 | — | — | WO | disclosed |
| WO-2015181061-A1 | 5-OXA-2-AZABICYCLO[2.2.2]OCTAN-4-YL AND 5-OXA-2-AZABICYCLO[2.2.1]HEPTAN-4-YL DERIVATIVES AS TAAR1 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-12-03 | — | — | WO | disclosed |
| WO-2015140658-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC AND RELATED DISORDERS | PFIZER INC. (US) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137435-A1 | 2-OXA-5-AZABICYCLO[2.2.1]HEPTAN-3-YL DERIVATIVES | HCRTR2, HCRTR1, CYP11B2 | NNMT 2319/4885SMN1; SMN2 1282/4885PARP10 3058/4885 |
| US-20170066775-A1 | 5-OXA-2-AZABICYCLO[2.2.2]OCTAN-4-YL AND 5-OXA-2-AZABICYCLO[2.2.1]HEPTAN-4-YL DERIVATIVES | GRIN2C, NR3C2, HTR2C | NNMT 1289/4885SMN1; SMN2 1052/4885PARP10 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.